Vericel Corp
corporate_fare Company Profile
Vericel Corp (NASDAQ:VCEL) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 14 items for VCEL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 14 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for VCEL spans 10-Q, 8-K, 10-K.
Recent high-impact activity:
- Vericel 10-Q Confirms Q3 Net Income of $14.2M on $85.4M Revenue, $235.6M in Cash and Investments
- Vericel Beats on Q3, Raises 2026 Revenue Guidance to $344-$346M
- Vericel Posts $14.2M Q3 Net Income, Swinging Sharply Higher
- Vericel Turns Profitable in Q2, Authorizes $200M Buyback, and Locks in BARDA Pact
- Vericel lifts 2026 guidance on 22% revenue growth and launches $200M buyback
Financial Snapshot
Short Interest & Short Volume
9.83 days to coverFINRA reported short interest of 5,364,126 shares in VCEL as of the October 30, 2026 settlement, a 2.4% increase from the prior period — about 9.8 days to cover at its recent average daily volume. On November 19, 2026, 46.0% of VCEL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.